Roivant Sciences Ltd 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Roivant Sciences Ltd 's ROA in the first quarter of 2026?
Roivant Sciences Ltd recorded a cumulative net loss of $-415 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -6.8%.

However, within the Healthcare sector 277 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3097, from total ROA ranking in the fourth quarter of 2025 at 4032.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Total Assets Change	62.8 %	5 %	-24.72 %	-13.52 %	-18.7 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-415	-398	-1,006	-574	-688
Return On Assets (TTM)	-6.8 %	-7.49 %	-19.19 %	-10.09 %	-11.69 %
ROIV's Total Ranking	# 3097	# 4032	# 3289	# 3352	# 3103
Total Assets (TTM) in million	8,193	5,709	5,437	5,063	5,033
Seq. Total Assets Change	43.52 %	5 %	7.39 %	0.6 %	-7.44 %
Seq. Net Income Change	-	-	-	-	-

ROIV's 5 Years Annual ROA >> Back to ROIV Management Effectiveness >> Compare ROIV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 96
Sector	# 278
Overall	# 3081

Return On Assets Statistics
High	Average	Low
125.22 %	-1.23 %	-53.91 %
(Dec 31 2023)		(Dec 31 2022)

News about Roivant Sciences Ltd Return on Assets ROA

Roivant's Brepocitinib Shows Impressive Efficacy in NIU Study, Shares Authorized for Repurchase of Sumitomo Pharma Stake

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant (Nasdaq: ROIV) and Priovant Therapeutics have recently shared promising results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU). These results have shown the strongest efficacy data for NIU observed to date, providing hope for patients suffering from this condition.
In addition to the successful NEPTUNE study, Roivant s board of directors has authorized a share repurchase program for up to $1.5 billion of the company s common shares. This program includes the repurchase of all 71.3 million shares currently held by Sumitomo Pharma. The purchase price for this transaction is set at $9.10 per share, totaling approximately $648.4 million. The repurchase of Sumitomo Pharma s stake will also lead to a reduction in Roivant s outstanding shares by about 9% as of February 9, 2024.

Financial Statements
Roivant Sciences Ltd 's Assets	$ 8,193 million	ROIV's Balance sheet
Roivant Sciences Ltd 's Income	$ -291 million	Quarterly ROIV's Income Statement
ROIV's Income by Division		See ROIV's Income by Division

Annual Return On Assets	(Mar 31 2026) FY 2025	(Mar 31 2025) FY 2024	(Mar 31 2024) FY 2023	(Mar 31 2022) FY 2022	FY
Y / Y Total Assets Change	13.15 %	-30.15 %	229.58 %	-	-
Total Assets in million	5,709	5,045	7,222	2,191	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-398	-357	4,231	-924	0
Annual Return On Assets	-6.97 %	-7.07 %	58.58 %	-42.17 %	-

ROIV's 5 Years Annual ROA >> Back to ROIV Management Effectiveness >> Compare ROIV ROA to its Competitors

More Return On Assets Ratios
ROIV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ROIV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ROIV's Competitors
Subscribers only: Roa for Roivant Sciences Ltd 's Suppliers
Subscribers only: Return On Assets for ROIV's Customers

You may also want to know
ROIV's Roi	ROIV's Inventory Turnover Ratio	ROIV's Growth Rates	ROIV's Dividend Comparisons
	ROIV's Profitability Ratios	ROIV's Asset Turnover Ratio	ROIV's Dividend Growth
ROIV's Roe	ROIV's Valuation Ratios	ROIV's Financial Strength Ratios	ROIV's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T15:28:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.